|
Australia-QLD-MAREEBA selskapets Kataloger
|
Firma Nyheter:
- Regulators Approve Lenacapavir for H. I. V. Prevention - The New York Times
Regulators Approve a Twice-Yearly Shot to Prevent H I V Infection The drug could change the course of the AIDS epidemic But the Trump administration has gutted the programs that might have paid
- Twice-a-year shot to prevent HIV approved in U. S. | CBC News
Gilead's drug is already sold to treat HIV under the brand name Sunlenca, which is listed as approved in Health Canada's database The prevention dose will be sold under a different name, Yeztugo
- FDA approves lenacapavir as a twice-a-year shot to prevent HIV | AP News
WASHINGTON (AP) — The U S has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U S and abroad will get access to the powerful new option While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called
- Regulators Approve a Twice-Yearly Shot to Prevent H. I. V. Infection
The approval is among the most anticipated developments in the prevention of H I V But it arrives during deep cuts to global health programs that were expected to purchase and distribute the drug in low-income countries The post Regulators Approve a Twice-Yearly Shot to Prevent H I V Infection appeared first on New York Times Share 196
- HIV prevention drug lenacapavir approved by FDA as twice-yearly . . .
Why FDA approval of new HIV prevention drug is a big deal 02:25 The U S Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV
- FDA Approves Twice-Yearly HIV Prevention Drug
Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service
- FDA Approves Game-Changing Twice-Yearly Shot for HIV Prevention
A significant advancement in the fight against the HIV epidemic has arrived, as the U S Food and Drug Administration (FDA) has approved a pioneering twice-yearly injection designed to prevent HIV infection The drug, known as lenacapavir (brand name Yeztugo), offers a potentially transformative alternative to existing daily oral prevention
- FDA approval of injectable lenacapavir marks progress for HIV prevention
The World Health Organization (WHO) welcomes the approval by the United States Food and Drug Administration (FDA) of injectable lenacapavir for HIV prevention This milestone follows promising 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated the safety and efficacy of lenacapavir across diverse populations and settings
- Global Health Watch: LEN for PrEP approved by US FDA, South Africa’s . . .
June 20, 2025 This week, we cover the US FDA approval of injectable lenacapavir (LEN) for PrEP, the “most transformative prevention product we’ve had in 44 years of this epidemic”, which demands urgent action if the remarkable science is translated into public health impact Plus, updates on South Africa’s HIV program in crisis, oversight changes on NIH’s HIV clinical guidelines
- Regulators Approve Lenacapavir for H. I. V. Prevention
The Food and Drug Administration on Wednesday approved a twice-yearly injection that provided a near-perfect shield against H I V infection in clinical trials The approval is among the most anticipated developments in the prevention of H I V
|
|